title: Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review.
abstract: BACKGROUND
  Ophthalmic artery chemosurgery (OAC) for retinoblastoma was introduced by us 5 years ago for advanced intraocular retinoblastoma. Because the success was higher than with existing alternatives and systemic side effects limited we have now treated less advanced intraocular retinoblastoma (Reese-Ellsworth (RE) I-III and International Classification Retinoblastoma (ICRB) B and C).
  
  
  RESULTS
  Retrospective review of 5 year experience in eyes with Reese Ellsworth (Table 1) I (7 eyes), II (6 eyes) or III (6 eyes) and/or International Classification (Table 2) B (19 eyes) and C (11 eyes) treated with OAC (melphalan with or without topotecan) introduced directly into the ophthalmic artery. Patient survival was 100%. Ocular event-free survival was 100% for Reese-Ellsworth Groups I, II and III (and 96% for ICRB B and C) at a median of 16 months follow-up. One ICRB Group C (Reese-Ellsworth Vb) eye could not be treated on the second attempt for technical reasons and was therefore enucleated. No patient required a port and only one patient required transfusion of blood products. The electroretinogram (ERG) was unchanged or improved in 14/19 eyes.
  
  
  CONCLUSIONS
  Ophthalmic artery chemosurgery for retinoblastoma that was Reese-Ellsworth I, II and III (or International Classification B or C) was associated with high success (100% of treatable eyes were retained) and limited toxicity with results that equal or exceed conventional therapy with less toxicity.
authors.affiliation: Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America. abramsod@mskcc.org
authors.forename: David H
authors.initials: DH
authors.lastname: Abramson
authors.forename: Brian P
authors.initials: BP
authors.lastname: Marr
authors.forename: Scott E
authors.initials: SE
authors.lastname: Brodie
authors.forename: Ira
authors.initials: I
authors.lastname: Dunkel
authors.forename: Sotiria
authors.initials: S
authors.lastname: Palioura
authors.forename: Y Pierre
authors.initials: YP
authors.lastname: Gobin
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005123:Eye / Q000187:drug effects / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use; D009880:Ophthalmic Artery / Q000187:drug effects / Q000473:pathology / Q000601:surgery*; D013508:Ophthalmologic Surgical Procedures / Q000379:methods; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D012175:Retinoblastoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D019772:Topotecan / Q000008:administration & dosage* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D019772:Topotecan; D008558:Melphalan